FDA
-
-
-
-
-
-
-
Medicenna raises CDN$4.44 million in public offering of units
-
-
-
-
-
-
-
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
-
-
-
-
-
-
-
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
-
-
-
-
-
-
-
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
-
-
-
-
-
-
-
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
-
-
-
-
-
-
-
Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
-
-
-
-
-
-
-
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeti
-
334,274 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


